Show simple item record

dc.contributor.authorHiller, L
dc.contributor.authorDunn, J
dc.contributor.authorLoi, S
dc.contributor.authorVallier, A
dc.contributor.authorHowe, D
dc.contributor.authorCameron, D
dc.contributor.authorMiles, D
dc.contributor.authorWardley, Andrew M
dc.contributor.authorEarl, H
dc.date.accessioned2018-05-13T19:43:29Z
dc.date.available2018-05-13T19:43:29Z
dc.date.issued2018-04-05
dc.identifier.citationAdjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. 2018, 18(1): 391 BMC Canceren
dc.identifier.issn1471-2407
dc.identifier.pmid29621991
dc.identifier.doi10.1186/s12885-018-4307-8
dc.identifier.urihttp://hdl.handle.net/10541/621003
dc.description.abstractTwelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost.
dc.language.isoenen
dc.rightsArchived with thanks to BMC canceren
dc.titleAdjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.en
dc.typeArticleen
dc.contributor.departmentWarwick Clinical Trials Unit, University of Warwick, Coventryen
dc.identifier.journalBMC Canceren
refterms.dateFOA2018-12-17T15:22:07Z
html.description.abstractTwelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost.


Files in this item

Thumbnail
Name:
document(1).pdf
Size:
889.0Kb
Format:
PDF
Description:
Full text, Open Access article

This item appears in the following Collection(s)

Show simple item record